FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
news.crunchbase23h
Funding Is Flush For Startups Focused On Treating Pain
As shares of Boston-based Vertex shot higher on the news of its non-opioid pill, Journavx, we took a look at investment in ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
The Business Journals9d
Vertex is hoping for 'historic' non-opioid painkiller approval. It might not be a straightforward blockbuster.
This week, the FDA is expected to release its approval decision for the non-opioid painkiller made by Vertex Pharmaceuticals Inc. The company that can capture the pain medicine market could hit a ...
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
WBUR6d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new ...
BioPharma Dive6d
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...
AFP6d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...